Cargando…

Increasing plasma ADAMTS13 activity is associated with HBeAg seroconversion in chronic hepatitis B patients during 5 years of entecavir treatment

The relationship between hemostatic system and HBeAg seroconversion (SC) of chronic hepatitis B (CHB) patients is ill-defined. We therefore evaluate the predictive value of plasma ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin motif repeats 13) and VWF (von Willebrand factor) fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Renyong, Xie, Yirui, Yang, Jiezuan, Lu, Haifeng, Ye, Ping, Jin, Linfeng, Lin, Wenqin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459868/ https://www.ncbi.nlm.nih.gov/pubmed/30976044 http://dx.doi.org/10.1038/s41598-019-42421-5

Ejemplares similares

Plasma Level of ADAMTS13 or IL-12 as an Indicator of HBeAg Seroconversion in Chronic Hepatitis B Patients Undergoing m-ETV Treatment
por: Yang, Jiezuan, et al.
Publicado: (2020)

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients
por: Yang, Jiezuan, et al.
Publicado: (2014)

Slow reduction of IP-10 Levels predicts HBeAg seroconversion in chronic hepatitis B patients with 5 years of entecavir treatment
por: Guo, Renyong, et al.
Publicado: (2016)

Seroconversion of Hepatitis B Envelope Antigen (HBeAg) by Entecavir in a Child with Chronic Hepatitis B
por: Hasosah, Mohammed Y., et al.
Publicado: (2012)

Manifestations of Perihepatic Lymph Nodes in Acute Flare of Chronic Hepatitis B: Association with HBeAg Status and with HBeAg Seroconversion
por: Ko, Yen-Ling, et al.
Publicado: (2015)

HBV pregenome RNA as a predictor of spontanous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients
por: Song, Guangjun, et al.
Publicado: (2023)

Natural antibody IgG levels are associated with HBeAg-positivity and seroconversion in chronic hepatitis B patients treated with entecavir
por: Choi, Youkyung H., et al.
Publicado: (2022)

Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients
por: Luo, Hao, et al.
Publicado: (2019)

Predictive value of serum ALT and T-cell receptor beta variable chain for HBeAg seroconversion in chronic hepatitis B patients during tenofovir treatment
por: Yang, Jiezuan, et al.
Publicado: (2017)

Prediction of early HBeAg seroconversion by decreased titers of HBeAg in the serum combined with increased grades of lobular inflammation in the liver
por: Bae, Sung Kwan, et al.
Publicado: (2012)

Sequence analysis of integrated hepatitis B virus DNA during HBeAg-seroconversion
por: Budzinska, Magdalena Agnieszka, et al.
Publicado: (2018)

Differential Plasma MicroRNA Profiles in HBeAg Positive and HBeAg Negative Children with Chronic Hepatitis B
por: Winther, Thilde Nordmann, et al.
Publicado: (2013)

HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis
por: Xing, Tongjing, et al.
Publicado: (2017)

Frequency-dependent selection drives HBeAg seroconversion in chronic hepatitis B virus infection
por: Warner, Brook G., et al.
Publicado: (2013)

Profiling of Peripheral TRBV and CD4+CD25+ Treg in CHB Patients with HBeAg SC during TDF Treatment
por: Yang, Jiezuan, et al.
Publicado: (2023)

Association of virological breakthrough and clinical outcomes in entecavir-treated HBeAg-positive chronic hepatitis B
por: Huang, Yi-Jie, et al.
Publicado: (2019)

Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
por: Song, Byung-Cheol, et al.
Publicado: (2014)

Efficacy Comparison of Tenofovir and Entecavir in HBeAg-Positive Chronic Hepatitis B Patients with High HBV DNA
por: Shi, Hong, et al.
Publicado: (2016)

Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected Individuals
por: Matthews, Gail V., et al.
Publicado: (2013)

Correlations of HBV Genotypes, Mutations Affecting HBeAg Expression and HBeAg/ anti-HBe Status in HBV Carriers
por: Lim, Chee Kent, et al.
Publicado: (2006)

On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B
por: Huang, Yi-Jie, et al.
Publicado: (2017)

The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B
por: He, Yi, et al.
Publicado: (2022)

Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients
por: Keshvari, Maryam, et al.
Publicado: (2015)

The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore
por: Lacey, L F, et al.
Publicado: (2007)

Impact of Drug-Resistance Polymerase Mutations on the Replication of HBeAg-Positive and HBeAg-Negative Hepatitis B Virus Strains in Vitro
por: Tacke, Frank, et al.
Publicado: (2012)

Different interventional criteria for chronic hepatitis B pregnant women with HBeAg(+) or HBeAg(-): Epidemiological data from Shaanxi, China
por: Chen, Tianyan, et al.
Publicado: (2018)

Is the function of the HBeAg really unknown?
por: Milich, David R.
Publicado: (2019)

Efficacy and Safety of Telbivudine Compared to Entecavir Among HBeAg+ Chronic Hepatitis B Patients: a Meta-Analysis Study
por: Liang, Jian, et al.
Publicado: (2013)

Meta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy
por: Zeng, Yu-Li, et al.
Publicado: (2021)

Analysis of clinical and virologic features in Hepatitis B e Antigen (HbeAg)-negative and HbeAg-positive Egyptian chronic hepatitis B patients
por: Fouad, Rabab, et al.
Publicado: (2020)

HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b
por: Ma, Hui, et al.
Publicado: (2016)

The presence of baseline HBsAb-Specific B cells can predict HBsAg or HBeAg seroconversion of chronic hepatitis B on treatment
por: Yin, Shengxia, et al.
Publicado: (2023)

HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection
por: Ferrando-Martinez, Sara, et al.
Publicado: (2019)

Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues
por: Wang, Yang, et al.
Publicado: (2022)

The decline of HBV RNA associated with HBeAg seroconversion and double-negative HBV DNA and RNA in chronic hepatitis B patients who received entecavir therapy: a 10-year retrospective cohort study
por: Ye, Feng, et al.
Publicado: (2022)

Dynamic changes of cytokine profiles and virological markers during 48 weeks of entecavir treatment for HBeAg-positive chronic hepatitis B
por: Li, Minghui, et al.
Publicado: (2022)

Caucasian Ethnicity, but Not Treatment Cessation Is Associated with HBsAg Loss Following Nucleos(t)ide Analogue-Induced HBeAg Seroconversion
por: Van Hees, Stijn, et al.
Publicado: (2019)

High-Throughput Analysis of the T Cell Receptor Beta Chain Repertoire in PBMCs from Chronic Hepatitis B Patients with HBeAg Seroconversion
por: Qu, Yachao, et al.
Publicado: (2016)

Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a
por: Jia, Wen, et al.
Publicado: (2019)

Effect of WSP, a Chinese Herbal Formula, on Th17/Treg Ratio and HBeAg Seroconversion in Telbivudine-Treated HBeAg-Positive Chronic Hepatitis B Patients with High Baseline ALT Levels (20–30 Times the ULN)
por: Zhang, Yang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_strcr063op93klll7o0uolokje